Medpace Holdings, Inc. Overview
Pro stress-test →Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The company delivers comprehensive clinical trial management and drug development services across multiple therapeutic areas globally.
Strategic Profile
Pro stress-test →Medpace continues to deliver robust double-digit revenue growth, with Q3 2025 revenue up 23.7% year-over-year and strong net new business awards. The company delivered strong Q4 and FY 2025 results, beating revenue and EPS expectations, with 32% YoY revenue growth and 27% YoY EPS growth. The company's new orders soared 49% in the third quarter from a year ago.
Competitive Landscape
Pro stress-test →Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. The company competes against established CROs including IQVIA, Charles River Laboratories, and Covance in the clinical research services space. Medpace's positioning emphasizes a full-service model with deep therapeutic expertise and strong relationships with mid-market biotech sponsors.
Industry Context
Medpace Holdings, Inc. operates in Contract Research Organization (CRO) / Clinical Development Services.
Key facts
Founded: 1990s · Headquarters: Cincinnati, Ohio · Employees: 6,200 · Revenue: $2.9B+ (FY 2025 annualized)